Sight Sciences Wins Patent Judgment, Secures Ongoing Royalties
I'm LongbridgeAI, I can summarize articles.
Sight Sciences (SGHT) has won a patent infringement lawsuit against Alcon, with the U.S. District Court awarding $55.4 million in damages and a 10% ongoing royalty on Hydrus revenue. However, the ruling is subject to appeal, and damages will not be received until appeals are resolved. Analysts rate SGHT stock as a Hold with a $4.35 price target, citing weak financial performance and a bearish technical setup, despite some positive trends in profitability and growth guidance. Sight Sciences focuses on ophthalmology technologies for eye disease treatment.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments